Founded by myeloma research pioneer and oncologist, James R. Berenson, M.D., OncoTracker provides proprietary serum BCMA testing, patient-derived xenografts (PDX), access to an ongoing extensive library of clinically characterized biospecimens, and consultative services, to help pharmaceutical and biotechnology companies develop and evaluate new drugs. OncoTracker’s facilities, including a state-of-the-art GLP laboratory and biorepository, are ideally suited to support drug development and clinical studies worldwide. Located in West Hollywood, CA, the company has provided critical testing, biospecimens, patient-derived xenografts and consultative guidance to research institutions, pharmaceutical companies and contract research organizations around the world to further the development of BCMA-directed drugs. OncoTracker welcomes the opportunity to discuss how its unique testing services and programs may help your drug development needs.